• Publications
  • Influence
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
TLDR
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
TLDR
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
TLDR
Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
TLDR
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation and the only common dose-limiting adverse event was hyperglycemia.
...
...